Skip to main
SOLV

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 9%

Bulls say

Solventum is well-positioned in the healthcare market as the company has strong growth potential and is continuously making strategic acquisitions to supplement its growth. The separation of the Health Information Systems segment will likely increase the company's value and eliminate the conglomerate discount. Additionally, the company has raised its guidance for organic growth, adjusted EPS, and free cash flow, and it remains committed to share repurchases and evaluating potential dividends.

Bears say

Solventum is facing challenges as they strive to unlock the conglomerate discount by separating their HIS business and focusing on their remaining segments. Despite progress in their transformation and exceeding expectations in their Q1 results, they are facing risks such as higher costs associated with TSA agreements and potential competition. With a lower growth profile and a current P/E multiple of 12.5x, their stock may not be as attractive compared to their peers who trade at a higher multiple.

Solventum Corporation (SOLV) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Buy based on their latest research and market trends.

According to 11 analysts, Solventum Corporation (SOLV) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $90.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $90.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.